Active externally funded projects

NOR-SWITCH study: RCT on the safety on switching from originator drug Infliximab (Remicade) to biosimilar CT-P13 (Remsima). Assaying serum drug concentrations, anti-drug antibodies and establishing biobank. October 2014-December 2016: 1,7 mill. NOK.

International collaboration

Oneel Patel, Department of Surgery, Austin Health, University of Melbourne, Australia

 
Page visits: 475